Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Chronic Kidney Disease Associated Pruritus
NCT05075408Phase 3Completed
- Sponsor
- Galderma
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of nemolizumab in chronic kidney disease (CKD), sponsored by Galderma. Started Mar 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05075408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075408.